ロード中...
Sorafenib for the treatment of hepatocellular carcinoma
The multikinase inhibitor sorafenib, which inhibits targets related to tumor cell proliferation and angiogenesis, was the first systemic agent to demonstrate a significant improvement in the overall survival for patients with advanced hepatocellular carcinoma (HCC) in two large randomized controlled...
保存先:
| 出版年: | Hepat Oncol |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Future Medicine Ltd
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6095169/ https://ncbi.nlm.nih.gov/pubmed/30190954 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/hep.13.20 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|